Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.
2.

Megacities, migration and an evolutionary approach to bipolar disorder: a study of Sardinian immigrants in Latin America.

Carta MG, Moro MF, Piras M, Ledda V, Prina E, Stocchino S, Orrù G, Romano F, Brasesco MV, Freire RC, Nardi AE, Tondo L.

Braz J Psychiatry. 2019 Jul 1. pii: S1516-44462019005011102. doi: 10.1590/1516-4446-2018-0338. [Epub ahead of print]

3.

Discovery of novel hit compounds with broad activity against visceral and cutaneous Leishmania species by comparative phenotypic screening.

Lamotte S, Aulner N, Späth GF, Prina E.

Sci Rep. 2019 Jan 24;9(1):438. doi: 10.1038/s41598-018-36944-6. Erratum in: Sci Rep. 2019 Jul 9;9(1):10148.

4.

Non-invasive positive pressure ventilation in pneumonia outside Intensive Care Unit: An Italian multicenter observational study.

Brambilla AM, Prina E, Ferrari G, Bozzano V, Ferrari R, Groff P, Petrelli G, Scala R, Causin F, Noto P, Bresciani E, Voza A, Aliberti S, Cosentini R; 3P study group.

Eur J Intern Med. 2019 Jan;59:21-26. doi: 10.1016/j.ejim.2018.09.025. Epub 2018 Oct 25.

PMID:
30528840
5.

Who are the patients with tuberculosis who are diagnosed in emergency facilities? An analysis of treatment outcomes in the state of São Paulo, Brazil.

Ranzani OT, Rodrigues LC, Waldman EA, Prina E, Carvalho CRR.

J Bras Pneumol. 2018 Apr;44(2):125-133. doi: 10.1590/s1806-37562017000000384. Portuguese, English.

6.

New Sepsis Definition (Sepsis-3) and Community-acquired Pneumonia Mortality. A Validation and Clinical Decision-Making Study.

Ranzani OT, Prina E, Menéndez R, Ceccato A, Cilloniz C, Méndez R, Gabarrus A, Barbeta E, Bassi GL, Ferrer M, Torres A.

Am J Respir Crit Care Med. 2017 Nov 15;196(10):1287-1297. doi: 10.1164/rccm.201611-2262OC.

PMID:
28613918
7.

The enemy within: Targeting host-parasite interaction for antileishmanial drug discovery.

Lamotte S, Späth GF, Rachidi N, Prina E.

PLoS Negl Trop Dis. 2017 Jun 8;11(6):e0005480. doi: 10.1371/journal.pntd.0005480. eCollection 2017 Jun. Review.

8.

3D Microfabricated Scaffolds and Microfluidic Devices for Ocular Surface Replacement: a Review.

Prina E, Mistry P, Sidney LE, Yang J, Wildman RD, Bertolin M, Breda C, Ferrari B, Barbaro V, Hopkinson A, Dua HS, Ferrari S, Rose FRAJ.

Stem Cell Rev Rep. 2017 Jun;13(3):430-441. doi: 10.1007/s12015-017-9740-6. Review.

PMID:
28573367
9.

Effect of clinically approved HDAC inhibitors on Plasmodium, Leishmania and Schistosoma parasite growth.

Chua MJ, Arnold MS, Xu W, Lancelot J, Lamotte S, Späth GF, Prina E, Pierce RJ, Fairlie DP, Skinner-Adams TS, Andrews KT.

Int J Parasitol Drugs Drug Resist. 2017 Apr;7(1):42-50. doi: 10.1016/j.ijpddr.2016.12.005. Epub 2016 Dec 23.

10.

Invasive Disease vs Urinary Antigen-Confirmed Pneumococcal Community-Acquired Pneumonia.

Ceccato A, Torres A, Cilloniz C, Amaro R, Gabarrus A, Polverino E, Prina E, Garcia-Vidal C, Muñoz-Conejero E, Mendez C, Cifuentes I, Puig de la Bella Casa J, Menendez R, Niederman MS.

Chest. 2017 Jun;151(6):1311-1319. doi: 10.1016/j.chest.2017.01.005. Epub 2017 Jan 16.

PMID:
28093269
11.

High-flow nasal cannula in hypoxemic patients: should I stay or should I go?

Prina E, Brambilla AM, Cosentini R.

Intensive Care Med. 2017 Feb;43(2):291-292. doi: 10.1007/s00134-016-4620-0. Epub 2016 Nov 22. No abstract available.

PMID:
27878311
12.

Exploration of the imidazo[1,2-b]pyridazine scaffold as a protein kinase inhibitor.

Bendjeddou LZ, Loaëc N, Villiers B, Prina E, Späth GF, Galons H, Meijer L, Oumata N.

Eur J Med Chem. 2017 Jan 5;125:696-709. doi: 10.1016/j.ejmech.2016.09.064. Epub 2016 Sep 22.

PMID:
27721154
13.

New aspects in the management of pneumonia.

Prina E, Ceccato A, Torres A.

Crit Care. 2016 Oct 1;20(1):267. doi: 10.1186/s13054-016-1442-y. Review.

14.

Surface chemistry of Ti6Al4V components fabricated using selective laser melting for biomedical applications.

Vaithilingam J, Prina E, Goodridge RD, Hague RJM, Edmondson S, Rose FRAJ, Christie SDR.

Mater Sci Eng C Mater Biol Appl. 2016 Oct 1;67:294-303. doi: 10.1016/j.msec.2016.05.054. Epub 2016 May 13.

15.

A new photocrosslinkable polycaprolactone-based ink for three-dimensional inkjet printing.

He Y, Tuck CJ, Prina E, Kilsby S, Christie SDR, Edmondson S, Hague RJM, Rose FRAJ, Wildman RD.

J Biomed Mater Res B Appl Biomater. 2017 Aug;105(6):1645-1657. doi: 10.1002/jbm.b.33699. Epub 2016 May 14.

PMID:
27177716
16.

Identifying decreased diaphragmatic mobility and diaphragm thickening in interstitial lung disease: the utility of ultrasound imaging.

Santana PV, Prina E, Albuquerque AL, Carvalho CR, Caruso P.

J Bras Pneumol. 2016 Apr;42(2):88-94. doi: 10.1590/S1806-37562015000000266. English, Portuguese.

17.

From Drug Screening to Target Deconvolution: a Target-Based Drug Discovery Pipeline Using Leishmania Casein Kinase 1 Isoform 2 To Identify Compounds with Antileishmanial Activity.

Durieu E, Prina E, Leclercq O, Oumata N, Gaboriaud-Kolar N, Vougogiannopoulou K, Aulner N, Defontaine A, No JH, Ruchaud S, Skaltsounis AL, Galons H, Späth GF, Meijer L, Rachidi N.

Antimicrob Agents Chemother. 2016 Apr 22;60(5):2822-33. doi: 10.1128/AAC.00021-16. Print 2016 May.

18.

Community-acquired pneumonia.

Prina E, Ranzani OT, Torres A.

Lancet. 2015 Sep 12;386(9998):1097-108. doi: 10.1016/S0140-6736(15)60733-4. Epub 2015 Aug 12. Review.

PMID:
26277247
19.

Diagnostic methods to assess inspiratory and expiratory muscle strength.

Caruso P, Albuquerque AL, Santana PV, Cardenas LZ, Ferreira JG, Prina E, Trevizan PF, Pereira MC, Iamonti V, Pletsch R, Macchione MC, Carvalho CR.

J Bras Pneumol. 2015 Mar-Apr;41(2):110-23. doi: 10.1590/S1806-37132015000004474.

20.

Cross-linked poly(acrylic acids) microgels and agarose as semi-interpenetrating networks for resveratrol release.

Tunesi M, Prina E, Munarin F, Rodilossi S, Albani D, Petrini P, Giordano C.

J Mater Sci Mater Med. 2015 Jan;26(1):5328. doi: 10.1007/s10856-014-5328-8. Epub 2015 Jan 11.

PMID:
25577210
21.

Dyspnea of unknown cause. Think about diaphragm.

Santana PV, Prina E, Caruso P, Carvalho CR, Albuquerque AL.

Ann Am Thorac Soc. 2014 Dec;11(10):1656-9. doi: 10.1513/AnnalsATS.201404-181CC. Review. No abstract available.

PMID:
25549033
22.

Risk factors associated with potentially antibiotic-resistant pathogens in community-acquired pneumonia.

Prina E, Ranzani OT, Polverino E, Cillóniz C, Ferrer M, Fernandez L, Puig de la Bellacasa J, Menéndez R, Mensa J, Torres A.

Ann Am Thorac Soc. 2015 Feb;12(2):153-60. doi: 10.1513/AnnalsATS.201407-305OC.

PMID:
25521229
23.

Simultaneous multi-parametric analysis of Leishmania and of its hosting mammal cells: A high content imaging-based method enabling sound drug discovery process.

Forestier CL, Späth GF, Prina E, Dasari S.

Microb Pathog. 2015 Nov;88:103-8. doi: 10.1016/j.micpath.2014.10.012. Epub 2014 Oct 31. Review.

PMID:
25448129
24.

Nosocomial pneumonia in the intensive care unit: how should treatment failure be predicted?

Ranzani OT, Prina E, Torres A.

Rev Bras Ter Intensiva. 2014 Jul-Sep;26(3):208-11. English, Portuguese. No abstract available.

25.

Probing druggability and biological function of essential proteins in Leishmania combining facilitated null mutant and plasmid shuffle analyses.

Dacher M, Morales MA, Pescher P, Leclercq O, Rachidi N, Prina E, Cayla M, Descoteaux A, Späth GF.

Mol Microbiol. 2014 Jul;93(1):146-66. doi: 10.1111/mmi.12648. Epub 2014 Jun 3.

26.

Helmet CPAP vs. oxygen therapy in severe hypoxemic respiratory failure due to pneumonia.

Brambilla AM, Aliberti S, Prina E, Nicoli F, Del Forno M, Nava S, Ferrari G, Corradi F, Pelosi P, Bignamini A, Tarsia P, Cosentini R.

Intensive Care Med. 2014 Jul;40(7):942-9. doi: 10.1007/s00134-014-3325-5. Epub 2014 May 10. Erratum in: Intensive Care Med. 2014 Aug;40(8):1187.

PMID:
24817030
27.

Lung ultrasound in the evaluation of pleural effusion.

Prina E, Torres A, Carvalho CR.

J Bras Pneumol. 2014 Jan-Feb;40(1):1-5. doi: 10.1590/S1806-37132014000100001. English, Portuguese. No abstract available.

28.

Phenotyping community-acquired pneumonia according to the presence of acute respiratory failure and severe sepsis.

Aliberti S, Brambilla AM, Chalmers JD, Cilloniz C, Ramirez J, Bignamini A, Prina E, Polverino E, Tarsia P, Pesci A, Torres A, Blasi F, Cosentini R.

Respir Res. 2014 Mar 4;15:27. doi: 10.1186/1465-9921-15-27.

29.

Pharmacological assessment defines Leishmania donovani casein kinase 1 as a drug target and reveals important functions in parasite viability and intracellular infection.

Rachidi N, Taly JF, Durieu E, Leclercq O, Aulner N, Prina E, Pescher P, Notredame C, Meijer L, Späth GF.

Antimicrob Agents Chemother. 2014;58(3):1501-15. doi: 10.1128/AAC.02022-13. Epub 2013 Dec 23.

30.

[Leishmania epidemiology, diagnosis, chemotherapy and vaccination approaches in the international network of Pasteur Institutes].

Louzir H, Aoun K, Späth GF, Laouini D, Prina E, Victoir K, Bouratbine A.

Med Sci (Paris). 2013 Dec;29(12):1151-60. doi: 10.1051/medsci/20132912020. Epub 2013 Dec 20. French.

31.

High content analysis of primary macrophages hosting proliferating Leishmania amastigotes: application to anti-leishmanial drug discovery.

Aulner N, Danckaert A, Rouault-Hardoin E, Desrivot J, Helynck O, Commere PH, Munier-Lehmann H, Späth GF, Shorte SL, Milon G, Prina E.

PLoS Negl Trop Dis. 2013 Apr 4;7(4):e2154. doi: 10.1371/journal.pntd.0002154. Print 2013.

32.

Distinct transcriptional signatures of bone marrow-derived C57BL/6 and DBA/2 dendritic leucocytes hosting live Leishmania amazonensis amastigotes.

Giraud E, Lecoeur H, Soubigou G, Coppée JY, Milon G, Prina E, Lang T.

PLoS Negl Trop Dis. 2012;6(12):e1980. doi: 10.1371/journal.pntd.0001980. Epub 2012 Dec 13.

33.

Thrombocytosis is a marker of poor outcome in community-acquired pneumonia.

Prina E, Ferrer M, Ranzani OT, Polverino E, Cillóniz C, Moreno E, Mensa J, Montull B, Menéndez R, Cosentini R, Torres A.

Chest. 2013 Mar;143(3):767-775. doi: 10.1378/chest.12-1235.

PMID:
23187959
34.

Systemic corticosteroids for community-acquired pneumonia: reasons for use and lack of benefit on outcome.

Polverino E, Cillóniz C, Dambrava P, Gabarrús A, Ferrer M, Agustí C, Prina E, Montull B, Menendez R, Niederman MS, Torres A.

Respirology. 2013 Feb;18(2):263-71. doi: 10.1111/resp.12013.

PMID:
23134361
35.

The crystal structure of the MAP kinase LmaMPK10 from Leishmania major reveals parasite-specific features and regulatory mechanisms.

Horjales S, Schmidt-Arras D, Limardo RR, Leclercq O, Obal G, Prina E, Turjanski AG, Späth GF, Buschiazzo A.

Structure. 2012 Oct 10;20(10):1649-60. doi: 10.1016/j.str.2012.07.005. Epub 2012 Aug 9.

36.

Community-acquired pneumonia in outpatients: aetiology and outcomes.

Cillóniz C, Ewig S, Polverino E, Marcos MA, Prina E, Sellares J, Ferrer M, Ortega M, Gabarrús A, Mensa J, Torres A.

Eur Respir J. 2012 Oct;40(4):931-8. Epub 2012 Jan 20.

37.

Development of a SYBR green I based RT-PCR assay for yellow fever virus: application in assessment of YFV infection in Aedes aegypti.

Dash PK, Boutonnier A, Prina E, Sharma S, Reiter P.

Virol J. 2012 Jan 22;9:27. doi: 10.1186/1743-422X-9-27.

38.

A combined luciferase imaging and reverse transcription polymerase chain reaction assay for the study of Leishmania amastigote burden and correlated mouse tissue transcript fluctuations.

de La Llave E, Lecoeur H, Besse A, Milon G, Prina E, Lang T.

Cell Microbiol. 2011 Jan;13(1):81-91. doi: 10.1111/j.1462-5822.2010.01521.x. Epub 2010 Sep 16.

PMID:
20846338
39.

Sorting of Leishmania-bearing dendritic cells reveals subtle parasite-induced modulation of host-cell gene expression.

Lecoeur H, de La Llave E, Osorio Y Fortéa J, Goyard S, Kiefer-Biasizzo H, Balazuc AM, Milon G, Prina E, Lang T.

Microbes Infect. 2010 Jan;12(1):46-54. doi: 10.1016/j.micinf.2009.09.014. Epub 2009 Sep 26.

PMID:
19786115
40.

Imaging Leishmania development in their host cells.

Lang T, Lecoeur H, Prina E.

Trends Parasitol. 2009 Oct;25(10):464-73. doi: 10.1016/j.pt.2009.07.006. Epub 2009 Sep 4. Review.

PMID:
19734094
41.

Transcriptional signatures of BALB/c mouse macrophages housing multiplying Leishmania amazonensis amastigotes.

Osorio y Fortéa J, de La Llave E, Regnault B, Coppée JY, Milon G, Lang T, Prina E.

BMC Genomics. 2009 Mar 20;10:119. doi: 10.1186/1471-2164-10-119.

42.

Clinical features and management of primary biliary cirrhosis.

Crosignani A, Battezzati PM, Invernizzi P, Selmi C, Prina E, Podda M.

World J Gastroenterol. 2008 Jun 7;14(21):3313-27. Review.

43.

AffyGCQC: a web-based interface to detect outlying genechips with extreme studentized deviate tests.

Osorio Y Fortéa J, Prina E, Lang T, Milon G, Davory C, Coppée JY, Regnault B.

J Bioinform Comput Biol. 2008 Apr;6(2):317-34.

PMID:
18464325
44.

Leishmania DNA is rapidly degraded following parasite death: an analysis by microscopy and real-time PCR.

Prina E, Roux E, Mattei D, Milon G.

Microbes Infect. 2007 Sep;9(11):1307-15. Epub 2007 Jun 30.

45.

Unveiling pathways used by Leishmania amazonensis amastigotes to subvert macrophage function.

Osorio y Fortéa J, Prina E, de La Llave E, Lecoeur H, Lang T, Milon G.

Immunol Rev. 2007 Oct;219:66-74. Review.

PMID:
17850482
46.

Antileishmanial 2-substituted quinolines: in vitro behaviour towards biological components.

Desrivot J, Herrenknecht C, Ponchel G, Garbi N, Prina E, Fournet A, Bories C, Figadère B, Hocquemiller R, Loiseau PM.

Biomed Pharmacother. 2007 Aug;61(7):441-50. Epub 2007 Apr 2.

PMID:
17459651
47.

Configuration and leishmanicidal activity of (-)-argentilactone epoxides.

Cortés MJ, Armstrong V, Barrero AF, Bandoni AE, Priestap HA, Fournet A, Prina E.

Nat Prod Res. 2006 Sep;20(11):1008-14.

PMID:
17050183
48.

Monocyte/macrophage dysfunctions do not impair the promotion of myelofibrosis by high levels of thrombopoietin.

Wagner-Ballon O, Chagraoui H, Prina E, Tulliez M, Milon G, Raslova H, Villeval JL, Vainchenker W, Giraudier S.

J Immunol. 2006 Jun 1;176(11):6425-33.

49.

Studies on quinones. Part 39: Synthesis and leishmanicidal activity of acylchloroquinones and hydroquinones.

Valderrama JA, Zamorano C, González MF, Prina E, Fournet A.

Bioorg Med Chem. 2005 Jul 1;13(13):4153-9.

PMID:
15876538
50.

Screening of New Caledonian and Vanuatu medicinal plants for antiprotozoal activity.

Billo M, Fournet A, Cabalion P, Waikedre J, Bories C, Loiseau P, Prina E, de Arias AR, Yaluff G, Fourneau C, Hocquemiller R.

J Ethnopharmacol. 2005 Jan 15;96(3):569-75. Epub 2004 Dec 1.

PMID:
15619580

Supplemental Content

Support Center